JP2022513320A5 - - Google Patents

Info

Publication number
JP2022513320A5
JP2022513320A5 JP2021542090A JP2021542090A JP2022513320A5 JP 2022513320 A5 JP2022513320 A5 JP 2022513320A5 JP 2021542090 A JP2021542090 A JP 2021542090A JP 2021542090 A JP2021542090 A JP 2021542090A JP 2022513320 A5 JP2022513320 A5 JP 2022513320A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
mutation
flt3
itd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513320A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/054142 external-priority patent/WO2020072544A1/en
Publication of JP2022513320A publication Critical patent/JP2022513320A/ja
Publication of JP2022513320A5 publication Critical patent/JP2022513320A5/ja
Priority to JP2024106255A priority Critical patent/JP2024114967A/ja
Pending legal-status Critical Current

Links

JP2021542090A 2018-10-01 2019-10-01 Flt3が変異した血液のがんを処置する方法 Pending JP2022513320A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024106255A JP2024114967A (ja) 2018-10-01 2024-07-01 Flt3が変異した血液のがんを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862739802P 2018-10-01 2018-10-01
US62/739,802 2018-10-01
US201962838239P 2019-04-24 2019-04-24
US62/838,239 2019-04-24
PCT/US2019/054142 WO2020072544A1 (en) 2018-10-01 2019-10-01 Methods of treating flt3-mutated hematologic cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024106255A Division JP2024114967A (ja) 2018-10-01 2024-07-01 Flt3が変異した血液のがんを処置する方法

Publications (2)

Publication Number Publication Date
JP2022513320A JP2022513320A (ja) 2022-02-07
JP2022513320A5 true JP2022513320A5 (cg-RX-API-DMAC7.html) 2022-10-12

Family

ID=70054475

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021542090A Pending JP2022513320A (ja) 2018-10-01 2019-10-01 Flt3が変異した血液のがんを処置する方法
JP2024106255A Pending JP2024114967A (ja) 2018-10-01 2024-07-01 Flt3が変異した血液のがんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024106255A Pending JP2024114967A (ja) 2018-10-01 2024-07-01 Flt3が変異した血液のがんを処置する方法

Country Status (4)

Country Link
US (2) US20220008448A1 (cg-RX-API-DMAC7.html)
EP (1) EP3860655A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022513320A (cg-RX-API-DMAC7.html)
WO (1) WO2020072544A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113502332B (zh) * 2021-09-07 2021-12-17 广东永诺医疗科技有限公司 一种用于检测flt3基因突变的引物、探针及试剂盒
TW202333712A (zh) * 2021-12-22 2023-09-01 加拿大健康網路大學 於急性骨髓性白血病或淋巴瘤之治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10517876B2 (en) * 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
CN101360751B (zh) * 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物
EP3062809B1 (en) * 2013-10-31 2020-07-08 Biokine Therapeutics Ltd. A cxcr4 peptide inhibitor for use in treating acute myeloid leukemia with a flt3 mutation

Similar Documents

Publication Publication Date Title
US20230233563A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
Kim et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor
JP6769962B2 (ja) 癌治療のためのキナーゼ阻害剤プロドラッグ
TWI893039B (zh) 透過循環腫瘤dna分析之分子疾病評估之方法及系統
ES2742310T3 (es) Método y kit para la detección no invasiva de mutaciones del gen EGFR
JP7778753B2 (ja) テロメラーゼ阻害剤による治療から利益を得る可能性が高い患者を特定する方法
US20260043089A1 (en) Compositions and methods for detecting circulating tumor dna
JP2022527788A5 (cg-RX-API-DMAC7.html)
US20220175779A1 (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
US20220259677A1 (en) Markers for Determining Tumor Hypoxia
EP3773551B1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
US20180263979A1 (en) Combination of raf inhibitors and aurora kinase inhibitors
Widasari et al. A deep-sequencing method detects drug-resistant mutations in the hepatitis B virus in Indonesians
EP4013894A1 (en) Method for altering therapy of advanced non-small cell lung cancer patients based on analysis of ctdna
US20250101522A1 (en) Brca1 promoter methylation in sporadic breast cancer patients detected by liquid biopsy
WO2025246530A1 (en) Personalized anti-emetic treatment for chemotherapy-induced nausea and vomiting
US20240041998A1 (en) Methods and compositions for sensitizing prc2 mutant tumors to immune checkpoint blockade therapy
Sathiyamoorthy et al. Study on PIK3CA gene mutations in oral squamous cell carcinoma among South Indian populations
US12467087B1 (en) Sequencing methods with partitioning
US20240219403A1 (en) Methods for inhibiting kras oncoprotein through enhanced gtpase activity
Yassin et al. Internal tandem duplication of FLT3 gene in Egyptian pediatric acute myeloid leukemia and acute lymphoblastic leukemia
WO2025128887A1 (en) Methods and compositions for selective enrichment of methylation signal
JP2002544147A (ja) 伸張を阻害しない逆転写反応基質として許容されるヌクレオチド類似体の取り込みと重合による逆転写酵素の忠実度と達成度の制御法
WO2025122504A1 (en) Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2025137620A1 (en) Methods for high quality and high accuracy methylation sequencing